Skip to main navigation menu Skip to main content Skip to site footer

From the suspicious of neoplasm to the diagnosis of lysosomal storage disease: Gaucher disease, case report.

De una sospecha de neoplasia al diagnóstico de una enfermedad por almacenamiento lisosomal: enfermedad de Gaucher, un reporte de caso




Section
Clinic cases

How to Cite
From the suspicious of neoplasm to the diagnosis of lysosomal storage disease: Gaucher disease, case report.
Rev. colomb. hematol. oncol. [Internet]. 2024 Dec. 5 [cited 2024 Dec. 22];11(2):60-7. Disponible en: https://doi.org/10.51643/22562915.672

Dimensions
PlumX

Laura Camila Hurtado Ascanio,

Profesional en Fundación Santa Fe de Bogotá.


Paula Perez Henao,

Profesional en Fundación Santa Fe de Bogotá.


Guillermo Enrique Quintero Vega,

Especialista en Fundación Santa Fe de Bogotá.


Gaucher disease is the most common Lysosomal Storage Disease, it is caused by the defective function of the Glucosylceramidase enzyme that generates the accumulation of its substrate, glucosylceramide. Given that the signs and symptoms are very variable and depend on the organ affected by glucosylceramide deposition, it is relevant to know the key aspects of this pathology to be able to give an accurate diagnosis and thus timely treatment. Clinical case: A 50-year-old female patient presents with a history of hepatosplenomegaly, thrombocytopenia, and bone pain.  At first, a neoplasia was suspected, and a positon emission tomography was performed with foci of hypermetabolism and cytolytics in the axial and appendicular bone marrow, a bone marrow biopsy shows 90% involvement by histiocytes and evidence of decreased activity of Glucosylceramidase. Conclusions: Suspicion should be raisd and screening for Gaucher Disease must be done, in case of signs and symptoms such as splenomegaly, thrombocytopenia and/or bone pain. Taking in to account this is a  rare disease, the only way of making a diagnosis is thinking about it, and thus initiate the appropriate treatment that helps improve the quality of life of patients.


Article visits 71 | PDF visits 75


  1. Nguyen Y, Stirnemann J, Belmatoug N. La maladie de Gaucher: quand y penser? Rev Med Interne [Internet]. 2019;40(5):313-22. Disponible en: https://dx.doi.org/10.1016/j.revmed.2018.11.012
  2. Rosenbloom BE, Weinreb NJ. Gaucher disease: A comprehensive review. Crit Rev Oncog [Internet]. 2013;18(3):163-75. Disponible en: http://dx.doi.org/10.1615/critrevoncog.2013006060
  3. Roh J, Subramanian S, Weinreb NJ, Kartha RV. Gaucher disease – more than just a rare lipid storage disease. J Mol Med [Internet]. 2022;100(4):499-518. Disponible en: http://dx.doi.org/10.1007/s00109-021-02174-z
  4. Baris H N, Cohen IJ, Mistry PK. Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history. Pediatric endocrinology reviews. Pediatr Endocrinol Rev [Internet]. 2014;12(01):72-81. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520262/
  5. Mignot C, Gelot A, De Villemeur TB. Gaucher disease. Handbook of Clinical Neurology [Internet]. 2013;113:1709-1715. Disponible en: https://dx.doi.org/10.1016/B978-0-444-59565-2.00040-X
  6. Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, Berger MG. A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int. J. Mol. Sci [Internet]. 2017;18(2):441. Disponible en: https://dx.doi.org/10.3390/ijms18020441
  7. Kong W, Lu C, Ding Y, Meng Y. Update of treatment for Gaucher disease. European Journal of Pharmacology [Internet]. 2022;926:175023. Disponible en: https://dx.doi.org/10.1016/j.ejphar.2022.175023
  8. Gort L, Coll MJ. Diagnóstico, biomarcadores y alteraciones bioquímicasde la enfermedad de Gaucher. Med Clin (Barc) [Internet]. 2011 Sep;137 Suppl 1:12-6. Disponible en: https://dx.doi.org/10.1016/S0025-7753(11)70011-2. PMID: 22230120.
  9. Dandana A, Ben Khelifa S, Chahed H, Miled A, Ferchichi S. Gaucher Disease: Clinical, Biological and Therapeutic Aspects. Pathobiology [Internet]. 2016;83(1):13-23. Disponible en: https://dx.doi.org/10.1159/000440865. PMID: 26588331
  10. Stone WL, Basit H, Master SR. Gaucher Disease. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK448080/
  11. Puentes-Tellez M A, Lerma-Barbosa PA, Garzón-Jaramillo RG, Suarez DA, Espejo-Mojica AJ, Guevara JM,... Alméciga-Díaz CJ. A perspective on research, diagnosis, and management of lysosomal storage disorders in Colombia. Heliyon [Internet]. 2020 Mar 28;6(3):e03635. Disponible en: https://dx.doi.org/10.1016/j.heliyon.2020.e03635
  12. Özdemir GN, Gündüz E. Gaucher Disease for Hematologists. Turk J Haematol [Internet]. 2022 Jun 1;39(2):136-139. Disponible en: https://dx.doi.org/10.4274/tjh.galenos.2021.2021.0683. PMID: 35439918; PMCID: PMC9160697.
  13. Giuffrida G, Markovic U, Condorelli A. et al. Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review. Orphanet J Rare Dis [Internet]. 2023;18:27 Disponible en: https://doi.org/10.1186/s13023-023-02623-7
  14. Pastores GM, Hughes DA, Gaucher Disease. En Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Gripp KW, et al., editors. PubMed. Seattle (WA): University of Washington, Seattle; 1993. Disponible en: https://pubmed.ncbi.nlm.nih.gov/20301446/
  15. Nagral A. Gaucher Disease. Journal of Clinical and Experimental Hepatology [Internet]. 2014 Mar;4(1):37-50. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017182/pdf/main.pdf
Sistema OJS 3.4.0.7 - Metabiblioteca |